NCT00841568View on ClinicalTrials.gov

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

OPC-41061

orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.

Trial Locations (1)

Unknown

Kanto Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY